OM1 Doubles Lupus Dataset, Representing More Than 56,000 Patients Prospectively Followed With Deep Clinical Data

Leveraging real-world data and AI applications, OM1 is accelerating lupus research and generating treatment and patient insights

BOSTON--(BUSINESS WIRE)--OM1 a leading real-world data, outcomes and technology company with a focus on chronic conditions, today announced the expansion of its lupus dataset, PremiOM™ SLE. The enhancement doubles the patient data counts to more than 56,000 Systemic Lupus Erythematosus (SLE) patients with deep clinical data and expands the OM1 Immunology Real-World Data Network to include patients with Cutaneous Lupus Erythematosus (CLE) and Lupus Nephritis. The dataset enables faster, more cost-effective access to research-grade lupus data for understanding, comparing, and predicting treatment outcomes for patients.

The expansion comes at a critical time during Lupus Awareness Month, as the Lupus Foundation of America estimates 1.5 million Americans have a form of lupus, with 16,000 new cases diagnosed each year. Currently, there is no cure, limited treatment options are available, and little is known as to why certain patients develop the disease and present with varying symptoms. What’s more, disparities within the community are prevalent with 90% of those suffering with lupus being women, and progression of SLE and severity are two to three times more common among Black and Latina women compared with white women. With these known disparities, improved and more personalized insights are paramount to improving patient outcomes.

Real-world datasets paired with artificial intelligence (AI) extraction are proving critical in being able to accelerate research and better understand patient journeys. Using the insights gleaned from the PremiOM SLE dataset and OM1’s Immunology Real-World Data Network, the healthcare industry can uncover trends into unique treatment patterns and journeys, including impacts of social determinants of health, disease activity data, and disease severity scores, which have previously not been possible for the disease.

"Understanding real-world patterns of lupus across different patient populations is essential to improving patient outcomes. OM1 is proud to be building unique data assets and solutions focused on unlocking patient insights,” said Gary Curhan, Chief Medical Officer at OM1. “Through improved understanding of diagnosis, progression, and treatment, the industry can break down barriers of care and disparities for these patients.”

To learn more about the OM1’s lupus dataset, data networks, and collaborations, please email [e-mail] or visit www.om1.com.

About OM1

OM1 is re-imagining real-world data and evidence by developing large, electronically-connected networks of health data in immunology, cardiometabolic, mental health, neuroscience, respiratory, and ENT specialty areas. Leveraging its extensive clinical networks, unparalleled technology, and industry-leading artificial intelligence platform, OM1 offers enriched healthcare datasets, advanced platforms for regulatory-compliant real-world studies, and personalized medicine solutions. With a focus on deep clinical insights, the offerings are used to unlock the power of healthcare data to measure and predict outcomes, accelerate medical research, and improve clinical decision making.